TSCAN THERAPEUTICS, INC. (TCRX) Operating Margin
- Operating margin · 12 months: Value -1695.15%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -1695.15% | Operating income / revenue. Period ending 2026-06-30. $-120.54M ÷ $7.11M × 100 ≈ -1695.15% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -120.54M USD | Operating Income (Loss) |
| Revenue | 7.11M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 97.03M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-120.54M | $7.11M | (m) | $97.03M | (m) | -1695.15% |
| 2026-03-31 | $-128.70M | $9.14M | (m) | $106.27M | (m) | -1408.73% |
| 2025-12-31 | $-135.81M | $10.32M | (m) | $114.15M | (m) | -1315.38% |
| 2025-09-30 | $-148.67M | $8.42M | (m) | $123.47M | (m) | -1765.01% |
| 2025-06-30 | $-144.24M | $6.96M | (m) | $118.04M | (m) | -2072.07% |
| 2025-03-31 | $-139.70M | $4.42M | (m) | $112.28M | (m) | -3159.87% |
| 2024-12-31 | $-134.82M | $2.82M | (m) | $107.35M | (m) | -4787.68% |
| 2024-09-30 | $-119.47M | $9.36M | (m) | $100.40M | (m) | -1276.07% |
| 2024-06-30 | $-111.59M | $12.20M | (m) | $96.88M | (m) | -914.69% |
| 2024-03-31 | $-102.09M | $14.81M | (m) | $91.23M | (m) | -689.22% |
| 2023-12-31 | $-93.46M | $21.05M | (m) | $88.15M | (m) | -444.00% |
| 2023-09-30 | $-90.75M | $16.93M | (m) | $81.35M | (m) | -535.94% |
| 2023-06-30 | $-82.58M | $16.41M | (m) | $73.64M | (m) | -503.26% |
| 2023-03-31 | $-73.22M | $17.32M | (m) | $66.91M | (m) | -422.80% |
| 2022-12-31 | $-66.64M | $13.54M | (m) | $59.82M | (m) | -492.32% |
| 2022-09-30 | $-62.19M | $13.29M | (m) | $56.82M | (m) | -467.80% |
| 2022-06-30 | $-61.45M | $12.34M | (m) | $56.00M | (m) | -497.88% |
| 2022-03-31 | $-56.89M | $11.13M | (m) | $52.30M | (m) | -510.88% |
| 2021-12-31 | $-48.64M | $10.14M | (m) | $44.95M | (m) | -479.65% |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-26.23M | $1.08M | (m) | $20.58M | (m) | -2417.79% |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B |